Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
Sun K, Chen WM, Wang X, Zhao XS, Li LD, Hao Y, Wang J, Xu N, Jiang Q, Jiang H, Xu LP, Wang Y, Zhang XH, Huang XJ, Qin YZ.
Sun K, et al. Among authors: xu n, xu lp.
Hematol Oncol. 2023 Aug;41(3):594-597. doi: 10.1002/hon.3114. Epub 2022 Dec 19.
Hematol Oncol. 2023.
PMID: 36516881
No abstract available.